Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2026
Comparing a Red and Blue Light-Emitting Diode Light Device With an Existing Blue Light Device for At-Home Treatment of Inflammatory Acne: An Open-Label Randomized-Controlled Trial.
СтатьяРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Friedmann Daniel P, Verma Kritin K, Gidwani Karan A, Nguyen Megan, Gharibvand Lida
Аннотация
BACKGROUND: Red and blue light have beneficial, complementary effects on acne.
OBJECTIVE: To evaluate the efficacy and safety of at-home treatment of mild-to-moderate inflammatory acne with an investigational combination 660-nm red/415-nm blue light-emitting diode device (RBL) compared with a commercially available 415-nm blue light-emitting diode device (BL).
MATERIALS AND METHODS: This was an open-label randomized-controlled trial with a 30-subject goal ( n = 20 RBL, n = 10 BL). Subjects performed once-daily at-home treatments for 8 weeks, with 4-week (4W) and 8-week (8W) follow-ups.
RESULTS: Twenty-three subjects completed the study ( n = 14 RBL, n = 9 BL). Total lesions were significantly reduced at 4W ( p = .028) and 8W ( p = .015) with RBL but at neither timepoint with BL. Inflammatory lesions were significantly reduced at 4W ( p = .010 and p = .008) and 8W ( p = .005 and p = .02) with both RBL and BL, respectively. Noninflammatory lesion reduction was not significant in either group. No significant between-group difference in total, inflammatory, or noninflammatory lesion reduction occurred at any timepoint. Median investigator static global assessment was significantly lower with RBL at 8W ( p = .015).
CONCLUSION: Daily at-home treatment with RBL led to significantly reduced inflammatory and total acne lesions at 4W and 8W. Although equivalent to BL in most outcomes, RBL demonstrated a significantly greater reduction in median ISGA.
OBJECTIVE: To evaluate the efficacy and safety of at-home treatment of mild-to-moderate inflammatory acne with an investigational combination 660-nm red/415-nm blue light-emitting diode device (RBL) compared with a commercially available 415-nm blue light-emitting diode device (BL).
MATERIALS AND METHODS: This was an open-label randomized-controlled trial with a 30-subject goal ( n = 20 RBL, n = 10 BL). Subjects performed once-daily at-home treatments for 8 weeks, with 4-week (4W) and 8-week (8W) follow-ups.
RESULTS: Twenty-three subjects completed the study ( n = 14 RBL, n = 9 BL). Total lesions were significantly reduced at 4W ( p = .028) and 8W ( p = .015) with RBL but at neither timepoint with BL. Inflammatory lesions were significantly reduced at 4W ( p = .010 and p = .008) and 8W ( p = .005 and p = .02) with both RBL and BL, respectively. Noninflammatory lesion reduction was not significant in either group. No significant between-group difference in total, inflammatory, or noninflammatory lesion reduction occurred at any timepoint. Median investigator static global assessment was significantly lower with RBL at 8W ( p = .015).
CONCLUSION: Daily at-home treatment with RBL led to significantly reduced inflammatory and total acne lesions at 4W and 8W. Although equivalent to BL in most outcomes, RBL demonstrated a significantly greater reduction in median ISGA.